Abstract
There are differences regarding to what extent the inclusion of productivity losses/gains in cost-effectiveness analyses (CEAs), including cost-utility analyses (CUAs). We conducted a systematic review of CEAs and CUAs of drugs for chronic immune-mediated disorders to understand how cost elements and cost calculation methods related to productivity losses/gains are used and examine the impact of including productivity costs on economic outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
